Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D–mutant solid tumors.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Fudan University, Zhongshan Hospital, Shanghai East Hospital, Shandong Tumor Hospital, Peking Union Medical College Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Hunan Cancer Hospital, Jiangsu Province Hospital, Guangdong Pharmaceutical University, First Affiliated Hospital of Guangdong Pharmaceutical University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162556914